Bosutinib and exemestane (EXE) versus EXE alone in postmenopausal (postm) women with hormone receptor-positive (HR+) HER2-negative (HER2-) advanced breast cancer (ABC).

被引：1
|
作者：
Moy, B.
Lebrun, F.
Bellet, M.
Chow, L.
Lang, I.
Xu, B.
Badwe, R. A.
Hershman, D. L.
Leip, E.
Bardy-Bouxin, N.
Duvillie, L.
Neven, P.
机构：
[1] Massachusetts Gen Hosp, Boston, MA 02114 USA
[2] Inst Jules Bordet, B-1000 Brussels, Belgium
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Unimed Med Inst, Comprehens Ctr Breast Dis, Hong Kong, Hong Kong, Peoples R China
[5] Orszagos Onkol Intezet, Budapest, Hungary
[6] Chinese Acad Med Sci, Canc Hosp, Beijing 100730, Peoples R China
[7] Tata Mem Hosp, Bombay 400012, Maharashtra, India
[8] Columbia Univ, Med Ctr, New York, NY USA
[9] Pfizer Inc, Cambridge, MA USA
[10] Pfizer Global Res & Dev, Paris, France
[11] UZ Leuven, Louvain, Belgium
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.631
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
631
引用
收藏
页数：1
相关论文
共 50 条
  • [41] CDK4/6 inhibition and endocrine therapy (ET) in the HER2-enriched subtype (HER2-E) in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (ABC): A retrospective analysis of real-world data
    Martinez-Saez, O.
    Tolosa, P.
    Sanchez De Torre, A.
    Pascual, T.
    Braso-Maristany, F.
    Rodriguez Hernandez, A.
    Parrilla, L.
    Roncero, A. M.
    Ruano, Y.
    Chic, N.
    Schettini, F.
    Laguna, J. C.
    Sanfeliu Torres, E.
    Gonzalez-Farre, B.
    Vidal, M.
    Adamo, B.
    Guillen Sacoto, M. C.
    Munoz, M.
    Prat, A.
    Ciruelos, E. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S30 - S30
  • [42] Impact of Proton Pump Inhibitors (PPI) on Palbociclib (PAL) Outcomes in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer (HR+/HER2-ABC): Exploratory Analysis of the PARSIFAL Trial
    Di Cosimo, Serena
    Perez-Garcia, Jose Manuel
    Ezquerra, Meritxell Bellet
    Dalenc, Florence
    Gil, Miguel Gil
    Borrego, Manuel Ruiz
    Gavila, Joaquin
    Sampayo-Cordero, Miguel
    Aguirre, Elena
    Schmid, Peter
    Marme, Frederik
    Gligorov, Joseph
    Schneeweiss, Andreas
    Albanell, Joan
    Zamora, Pilar
    Wheatley, Duncan
    De Duenas, Eduardo Martinez
    Caranana, Vicente
    Amillano, Kepa
    Malfettone, Andrea
    Cortes, Javier
    Llombart-Cussac, Antonio
    CANCER RESEARCH, 2023, 83 (05)
  • [43] Management of hormone receptor-positive, HER2-negative early breast cancer
    Walsh, Elaine M.
    Smith, Karen L.
    Stearns, Vered
    SEMINARS IN ONCOLOGY, 2020, 47 (04) : 187 - 200
  • [44] APOBEC signature, clinical characteristics, and outcome in hormone receptor-positive (HR+) HER2-negative (HER2-) breast cancer (BC) patients (pts) in real-world data (RWD)
    Chumsri, Saranya
    Raskina, Kira
    Sammons, Sarah
    Alder, Laura
    Danziger, Natalie
    Schrock, Alexa B.
    McGregor, Kim
    Sokol, Ethan
    CANCER RESEARCH, 2022, 82 (04)
  • [45] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Xi Jin
    Yi-Fan Zhou
    Ding Ma
    Shen Zhao
    Cai-Jin Lin
    Yi Xiao
    Tong Fu
    Cheng-Lin Liu
    Yi-Yu Chen
    Wen-Xuan Xiao
    Ya-Qing Liu
    Qing-Wang Chen
    Ying Yu
    Le-Ming Shi
    Jin-Xiu Shi
    Wei Huang
    John F. R. Robertson
    Yi-Zhou Jiang
    Zhi-Ming Shao
    Nature Genetics, 2023, 55 : 1696 - 1708
  • [46] Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2-) breast cancer before chemo-endocrine therapy
    Du, L.
    Yau, C.
    Brown-Swigart, L.
    Gould, R.
    Krings, G.
    Hirst, G. L.
    Bedrosian, I
    Layman, R. M.
    Carter, J. M.
    Klein, M.
    Venters, S.
    Shad, S.
    van der Noordaa, M.
    Chien, A. J.
    Haddad, T.
    Isaacs, C.
    Pusztai, L.
    Albain, K.
    Nanda, R.
    Tripathy, D.
    Liu, M. C.
    Boughey, J.
    Schwab, R.
    Hylton, N.
    DeMichele, A.
    Perlmutter, J.
    Yee, D.
    Berry, D.
    van't Veer, L.
    Valero, V.
    Esserman, L. J.
    Symmans, W. F.
    ANNALS OF ONCOLOGY, 2021, 32 (05) : 642 - 651
  • [47] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Noguchi, Shinzaburo
    Masuda, Norikazu
    Iwata, Hiroji
    Mukai, Hirofumi
    Horiguchi, Jun
    Puttawibul, Puttisak
    Srimuninnimit, Vichien
    Tokuda, Yutaka
    Kuroi, Katsumasa
    Iwase, Hirotaka
    Inaji, Hideo
    Ohsumi, Shozo
    Noh, Woo-Chul
    Nakayama, Takahiro
    Ohno, Shinji
    Rai, Yoshiaki
    Park, Byeong-Woo
    Panneerselvam, Ashok
    El-Hashimy, Mona
    Taran, Tetiana
    Sahmoud, Tarek
    Ito, Yoshinori
    BREAST CANCER, 2014, 21 (06) : 703 - 714
  • [48] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
    Shinzaburo Noguchi
    Norikazu Masuda
    Hiroji Iwata
    Hirofumi Mukai
    Jun Horiguchi
    Puttisak Puttawibul
    Vichien Srimuninnimit
    Yutaka Tokuda
    Katsumasa Kuroi
    Hirotaka Iwase
    Hideo Inaji
    Shozo Ohsumi
    Woo-Chul Noh
    Takahiro Nakayama
    Shinji Ohno
    Yoshiaki Rai
    Byeong-Woo Park
    Ashok Panneerselvam
    Mona El-Hashimy
    Tetiana Taran
    Tarek Sahmoud
    Yoshinori Ito
    Breast Cancer, 2014, 21 : 703 - 714
  • [49] Real-world (RW) elacestrant use patterns and therapeutic outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC)
    Lloyd, Maxwell Roger
    Ali, Azka
    Weipert, Caroline M.
    Solomon, Sheila R.
    Saha, Jayati
    Lipsyc-Sharf, Marla
    Hamilton, Erika P.
    Kalinsky, Kevin
    Bardia, Aditya
    Zhang, Nicole
    Wander, Seth Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [50] Safety and Efficacy of Everolimus With Exemestane vs. Exemestane Alone in Elderly Patients With HER2-Negative, Hormone Receptor-Positive Breast Cancer in BOLERO-2
    Pritchard, Kathleen I.
    Burris, Howard A., III
    Ito, Yoshinori
    Rugo, Hope S.
    Dakhil, Shaker
    Hortobagyi, Gabriel N.
    Campone, Mario
    Csoszi, Tibor
    Baselga, Jose
    Puttawibul, Puttisak
    Piccart, Martine
    Heng, Daniel
    Noguchi, Shinzaburo
    Srimuninnimit, Vichien
    Bourgeois, Hugues
    Gonzalez Martin, Antonio
    Osborne, Karen
    Panneerselvam, Ashok
    Taran, Tetiana
    Sahmoud, Tarek
    Gnant, Michael
    CLINICAL BREAST CANCER, 2013, 13 (06) : 421 - U113
12345